A Study of MEDI5083 Alone and in Combination with Durvalumab in Selected Advanced Solid Tumors

Trial Identifier: D6840C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03089645
Start Date: March 2017
Primary Completion Date: June 2020
Study Completion Date: June 2020
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
Australia Clayton, Australia, 3168
Australia Melbourne, Australia, 3000
Australia Melbourne, Australia, 3004
Australia Randwick, Australia, 2031
United States of America, NJ Hackensack, NJ, United States of America, 07601
United States of America, RI Providence, RI, United States of America, 02903
United States of America, TN Nashville, TN, United States of America, 37203
United States of America, UT Salt Lake City, UT, United States of America, 84112